glp-1 cardiovascular outcomes 2025 news Risks after Discontinuation APhA 2025: GLP-1 Receptor Agonists

these can be used to help identify what might be contributing to any adverse symptoms

FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes

That means roughly 1,200 to 1,500 grams of water, about 2.5 to 3.3 pounds, can release as glycogen stores deplete

This is in line with previous observations that ICV administration of exendin-4 increases sympathetic outflow to brown adipose tissue (BAT) and WAT depots, resulting in increased thermogenesis and uptake of fatty acid (FA) to these tissues

Projected Prevalence of Obesity in Primary Total Knee Arthroplasty: How Big Will the Problem Get